Suven Life Sciences has been selected as one of the ‘Best Under A Billion’ companies by Forbes Asia 2014. Forbes Asia’s ‘Best Under A Billion’ list highlights 200 of the best small and midsized listed companies in Asia Pacific with annual revenue under $1 billion. To qualify for the selection, companies must have revenue between $5 million and $1 billion, positive net income and be publicly traded for at least a year.
From a universe of 17,000 companies, qualified candidates are screened on sales growth, earnings growth and return on equity. The result is a final list featuring 200 exceptional small and midsized companies from Asia Pacific.
In recognition of the achievement of these 200 ‘Best Under A Billion’ Companies, Forbes Asia is organizing an Award Ceremony and the company will receive this award on December 09, 2014 in Bangkok, Thailand.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.
